BTIG Research Reiterates Buy Rating for Hims & Hers Health (NYSE:HIMS)

Hims & Hers Health (NYSE:HIMS)‘s stock had its “buy” rating restated by BTIG Research in a research note issued on Tuesday,Benzinga reports. They currently have a $85.00 price objective on the stock. BTIG Research’s target price suggests a potential upside of 91.69% from the stock’s previous close.

A number of other equities analysts have also recently commented on the company. Bank of America increased their target price on Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a report on Tuesday. Truist Financial reduced their target price on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a report on Monday, August 18th. Wall Street Zen cut Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Canaccord Genuity Group reiterated a “buy” rating and issued a $68.00 price objective on shares of Hims & Hers Health in a research report on Friday, September 12th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Two research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Reduce” and an average price target of $43.58.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $44.34 on Tuesday. The stock’s 50-day moving average price is $51.42 and its 200-day moving average price is $50.73. Hims & Hers Health has a 52 week low of $19.15 and a 52 week high of $72.98. The stock has a market capitalization of $10.02 billion, a PE ratio of 55.43, a price-to-earnings-growth ratio of 3.15 and a beta of 2.25. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 3rd. The company reported $0.09 EPS for the quarter, meeting analysts’ consensus estimates of $0.09. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business had revenue of $598.98 million during the quarter, compared to analysts’ expectations of $578.99 million. During the same quarter in the prior year, the firm earned $0.32 earnings per share. The business’s revenue was up 49.2% compared to the same quarter last year. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities analysts expect that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 145,000 shares of the company’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $55.35, for a total transaction of $8,025,750.00. Following the transaction, the chief financial officer directly owned 128,984 shares in the company, valued at $7,139,264.40. This represents a 52.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Patrick Harrison Carroll sold 60,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total value of $3,214,800.00. Following the transaction, the insider owned 169,940 shares in the company, valued at $9,105,385.20. This trade represents a 26.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,432,271 shares of company stock valued at $74,229,585 over the last three months. 13.71% of the stock is currently owned by company insiders.

Institutional Trading of Hims & Hers Health

Large investors have recently modified their holdings of the stock. Quent Capital LLC purchased a new stake in shares of Hims & Hers Health during the third quarter worth $28,000. Virtus Advisers LLC purchased a new stake in shares of Hims & Hers Health during the second quarter worth $26,000. Quaker Wealth Management LLC purchased a new stake in shares of Hims & Hers Health during the second quarter worth $29,000. Bessemer Group Inc. increased its position in shares of Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after acquiring an additional 312 shares during the period. Finally, Hilltop National Bank purchased a new position in Hims & Hers Health in the third quarter valued at $35,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.